A systematic review 1 including 9 studies with a total of 19 569 subjects was abstracted in DARE. Coronary heart disease (CHD) patients aged 65 years or older were included. The statins used were simvastatin (20-40mg), pravastatin (40mg) or fluvastatin (80mg). All trials were double-blind, and all but one used an intention-to-treat analysis. Seven trials achieved a 95% follow-up rate. Statin use was associated with a reduction in all-cause mortality (RR 0.78, 95% CI 0.65 to 0.89) with NNT of 28. Statins reduced CHD mortality (RR 0.70, 95% CI 0.53 to 0.83) with NNT of 34. Non-fatal myocardial infarction was reduced in the statin group (RR 0.74, 95% CI 0.60 to 0.89) with NNT of 38. Need for revascularisation was reduced (RR 0.70, 95% CI 0.53 to 0.83) with NNT of 24. Stroke incidence was reduced (RR 0.75, 95% CI 0.56 to 0.94) with NNT of 58.
Primary/Secondary Keywords